Mark Boyd is Professor of Molecular Oncology in the Institute of Translational Medicine at the University of Liverpool. He joined the Alderley Park Lighthouse Lab to help with COVID-19 testing.
Lab Story – Prof Mark Boyd
Lighthouse Labs
Related Blogs
Science & Technology
Central Nervous System Drug...
Preclinical to clinical, building a translational link between in vitro and in vivo models of neuroinflammation for drug discovery.
Dr Emma Jones & Dr Lorna Fitzpatrick
September 2024
Biomarkers
Unleashing the Potential of Human T...
Dr Michael Eyres, Lead Scientist at MDC, has been working on applying MDCs biomarkers expertise to a novel approach in drug discovery.
July 2024
Intellectual Property
IP Protection Strategy: The Univers...
Dr Geraint Lewis, Head of Enterprise Services, Newcastle University
11 July 2024
Science & Technology
Accessing the Skills for Successful...
Graeme Wilkinson, Head of Virtual R&D, MDC
3 July 2024
Funding
The Importance of Being Pitch-Ready...
Michael Salako, Investment Director, Start Codon
28 June 2024
Partnership
How do I Find the Right CRO for my ...
Dr Mike Piper Chief Commercial Officer and Dr Angelo Pugliese, Head of In-silico Discovery, BioAscent
28 June 2024
Intellectual Property
Cost-effective IP Strategies: Spott...
Dr Catrina Carroll, Strategy Leader, Collaborative R&D and Licensing, MDC
13 June 2024
Funding
An Introduction to External Investm...
Mark Wyatt, Investment Director, Northern Gritstone
05 June 2024
Intellectual Property
Letting Technology Address the Chal...
Dr Rob Grundy, CEO, Intelligent OMICS
12 June 2024
Views from the Discovery Nation
Following on from Creating ...
Following on from Creating a Richer National R&D Pipeline with Professor Chris Molloy, in this blog, Tim Newton investigates the trends and challenges that shaped therapeutics financing from 2020 to mid-2023.
By Dr Tim Newton
23 May 2024
Views from the Discovery Nation
UK Life Sciences – The Future is ...
There are signs of recovery, but one that is in its very earliest stages. There is evidence of capital beginning to flow. However, not to all parts of our sector.
By Professor Chris Molloy, CEO at Medicines Discovery Catapult.
22 May 2024
Oncology
Greatly Enhancing the Capacity for ...
Detecting tumour DNA through liquid biopsies marks the new frontier in oncology, providing a wealth of critical data for drug development research.
Dr Andrzej Rutkowski, Lead Scientist at Medicines Discovery Catapult (MDC), illuminates the value of this pioneering approach.
Jump to Optimised Analysis of ctDNA
Jump to Customised and Differentiated Personalised Medicine Development Solutions
People Power
Dhifaf shares with us her e...
Which team do you work in and what does that team do? I work…
People Power
Mike gives us an insight in...
Which team do you work in and what does that team do? I work…
People Power
Juliana shares her 13 years...
Which team do you work in and what does that team do? I work…